One of the most significant developments in medical oncology practice has been the approval of various antiangiogenic drugs for the treatment of a number of different malignancies. These drugs include bevacizumab (Avastin®), the anti-VEGF monoclonal antibody. Thus far, bevacizumab appears to induce clinical benefit in patients who have advanced metastatic disease only or primarily when it is combined with conventional chemotherapy. The reasons for the chemo-enhancing effects of bevacizumab are unknown, and this is a subject that we have been actively studying along with additional ways that antiangiogenic drugs may be combined with chemotherapy. In this respect, we have focused much of our effort on metronomic low dose chemotherapy. We have been studying the hypothesis that some chemotherapy drugs at maximum tolerated doses or other cytotoxic- like drugs such as acute "vascular disrupting agents" (VDAs) can cause an acute mobilization of proangiogenic cells from the bone marrow which home to and colonize the treated tumors, thus accelerating their recovery. These cells include endothelial progenitor cells. This systemic process can be largely blocked by a targeted antiangiogenic drug, e.g. anti-VEGFR-2 antibodies. In addition, metronomic chemotherapy, i.e., close regular administration of chemotherapy drugs at low non-toxic doses with no breaks, over prolonged periods of time not only prevents the acute CEP bone marrow response, but can even target the cells. This potential antiangiogenic effect of metronomic chemotherapy can also be boosted by combination with a targeted antiangiogenic agent. Treatment combinations of metronomic chemotherapy and an antiangiogenic drug have moved into phase II clinical trial testing with particularly encouraging results thus far reported in metastatic breast and recurrent ovarian cancer. Oral chemotherapy drugs such as cyclophosphamide (CTX), methotrexate are the main chemotherapeutics used for such trials. Oral 5-FU prodrugs such as UFT would also appear to be highly suitable based on long term adjuvant therapy studies in patients. Recent preclinical results using metronomic cyclophosphamide and metronomic UFT in models of advanced metastatic breast cancer suggest that this type of combination might be particularly promising for metronomic chemotherapy in this indication, particularly when combined with a targeted antiangiogenic drug.

Citations

Citations to this article as recorded by  

• Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
  Piotr J. Wysocki, Mateusz Łobacz, Paweł Potocki, Łukasz Kwinta, Anna Michałowska-Kaczmarczyk, Agnieszka Słowik, Kamil Konopka, Anna Buda-Nowak
  Cancers.2023; 15(4): 1067.     CrossRef
• Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature
  Benjamin Carcamo, Giulio Francia
  Journal of Clinical Medicine.2022; 11(10): 2849.     CrossRef
• Muscarinic Receptors Associated with Cancer
  Gloria M. Calaf, Leodan A. Crispin, Juan P. Muñoz, Francisco Aguayo, Tammy C. Bleak
  Cancers.2022; 14(9): 2322.     CrossRef
• De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?
  Palma Fedele, Valeria Sanna, Alessandro Fancellu, Antonella Marino, Nicola Calvani, Saverio Cinieri
  Critical Reviews in Oncology/Hematology.2021; 157: 103148.     CrossRef
• Metronomics in Pediatric Oncology: Lessons Learned and the Way Forward
  Raja Pramanik, Sameer Bakhshi
  Indian Journal of Medical and Paediatric Oncology.2020; 41(03): 317.     CrossRef
• Optimal Impulsive Control With Application to Antiangiogenic Tumor Therapy
  Filippo Cacace, Valerio Cusimano, Pasquale Palumbo
  IEEE Transactions on Control Systems Technology.2020; 28(1): 106.     CrossRef
• Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma
  Shengnan Zhao, Yakun Zhang, Lei Wang, Li Yang, Liqun Zou, Fabao Gao
  Cancer Biology & Therapy.2019; 20(1): 65.     CrossRef
• Tumor endothelial cells as a potential target of metronomic chemotherapy
  Ji Yoon Kim, Young-Myeong Kim
  Archives of Pharmacal Research.2019; 42(1): 1.     CrossRef
• Analyses of the Temperature Field of a Piezoelectric Micro Actuator in the Endoscopic Biopsy Channel
  Pancheng Zhu, Hanmin Peng, Jianzhi Yang
  Applied Sciences.2019; 9(21): 4499.     CrossRef
• The use of low‐dose metronomic chemotherapy in dogs—insight into a modern cancer field
  T. B. Gaspar, J. Henriques, L. Marconato, F. L. Queiroga
  Veterinary and Comparative Oncology.2018; 16(1): 2.     CrossRef
• Dental pulp stem cells used to deliver the anticancer drug paclitaxel
  Hamideh Salehi, Siham Al-Arag, Elodie Middendorp, Csilla Gergely, Frederic Cuisinier, Valerie Orti
  Stem Cell Research & Therapy.2018;[Epub]     CrossRef
• Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
  William H. Isacoff, Howard A. Reber, Rudolph Bedford, William Hoos, Lola Rahib, Alexander Upfill-Brown, Timothy Donahue, O. Joe Hines
  Targeted Oncology.2018; 13(4): 461.     CrossRef
• Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
  John P. Fruehauf, Monica El-Masry, Katherine Osann, Basmina Parmakhtiar, Maki Yamamoto, James G. Jakowatz
  Cancer Chemotherapy and Pharmacology.2018; 82(2): 353.     CrossRef
• Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer
  Koji Harada, Tarannum Ferdous, Yoshiya Ueyama
  Japanese Dental Science Review.2017; 53(3): 61.     CrossRef
• Optimal discrete time control of antiangiogenic tumor therapy
  Dániel András Drexler, Johanna Sápi, Levente Kovács
  IFAC-PapersOnLine.2017; 50(1): 13504.     CrossRef
• Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
  Serena Mazzucchelli, Michela Bellini, Luisa Fiandra, Marta Truffi, Maria A. Rizzuto, Luca Sorrentino, Erika Longhi, Manuela Nebuloni, Davide Prosperi, Fabio Corsi
  Oncotarget.2017; 8(5): 8383.     CrossRef
• Penetration and Silencing Activity of VEGF Dicer Substrate siRNA Vectorized by Chitosan Nanoparticles in Monolayer Culture and a Solid Tumor ModelIn Vitrofor Potential Application in Tumor Therapy
  Maria Abdul Ghafoor Raja, Haliza Katas, Zariyantey Abd Hamid
  Journal of Nanomaterials.2016; 2016: 1.     CrossRef
• Maintenance Treatment with Oral Cyclophosphamide and Bevacizumab in Patients with Recurrent Epithelial Ovarian Cancer
  Roberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, Letizia Laera, Salvatora Tindara Miano, Daniele Marrelli, Franco Roviello, Vincenzo Bianco, Edoardo Francini
  Future Oncology.2015; 11(18): 2563.     CrossRef
• Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
  Teresa Di Desidero, Ping Xu, Shan Man, Guido Bocci, Robert S. Kerbel
  Oncotarget.2015; 6(40): 42396.     CrossRef
• Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
  Ho-Suap Hahn, Ki-Heon Lee, In-Ho Lee, Jae-Ho Lee, Chang-Sung Whang, Yeong-Woo Jo, Tae-Jin Kim
  Journal of Gynecologic Oncology.2014; 25(2): 130.     CrossRef
• Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
  Gabriella Ferrandina, Giacomo Corrado, Floriana Mascilini, Paola Malaguti, Riccardo Samaritani, Mariagrazia Distefano, Valeria Masciullo, Alessia Di Legge, Antonella Savarese, Giovanni Scambia
  BMC Cancer.2014;[Epub]     CrossRef
• Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer
  Yuji Ikeda, Masashi Takano, Katsutoshi Oda, Hiroko Kouta, Tomoko Goto, Kazuya Kudoh, Naoki Sasaki, Tsunekazu Kita, Yoshihiro Kikuchi
  International Journal of Gynecological Cancer.2013; 23(2): 355.     CrossRef
• Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells
  TARANNUM FERDOUS, KOJI HARADA, TAKANORI KIN, TOYOKO HARADA, YOSHIYA UEYAMA
  International Journal of Oncology.2013; 43(1): 271.     CrossRef
• Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
  Yoshinori Ito, Takuji Iwase, Kiyohiko Hatake
  Breast Cancer.2012; 19(3): 206.     CrossRef
• First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study
  Veronica Marchetti, Mario Giorgi, Anna Fioravanti, Riccardo Finotello, Simonetta Citi, Bastianina Canu, Paola Orlandi, Teresa Di Desidero, Romano Danesi, Guido Bocci
  Investigational New Drugs.2012; 30(4): 1725.     CrossRef
• Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
  Manuela Miscoria, Fabrizio Tonetto, Laura Deroma, Piernicola Machin, Carla Di Loreto, Pamela Driol, Alessandro Marco Minisini, Stefania Russo, Claudia Andreetta, Mauro Mansutti, Giuseppe Damante, Gianpiero Fasola, Fabio Puglisi
  Anti-Cancer Drugs.2012; 23(3): 326.     CrossRef
• Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
  Uzma Asghar, Tim Meyer
  Journal of Hepatology.2012; 56(3): 686.     CrossRef
• Metronomic therapy for gynecologic cancers
  Wen-Hsiang Su, Tien-Yu Ho, Yiu-Tai Li, Chien-Hsing Lu, Wen-Ling Lee, Peng-Hui Wang
  Taiwanese Journal of Obstetrics and Gynecology.2012; 51(2): 167.     CrossRef
• Controlling escape from angiogenesis inhibitors
  Barbara Sennino, Donald M. McDonald
  Nature Reviews Cancer.2012; 12(10): 699.     CrossRef
• Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer
  Ursula A. Matulonis, Lauren Pereira, Joyce Liu, Hang Lee, Julie Lee, Christin Whalen, Susana Campos, Tina Atkinson, Margaret Hill, Suzanne Berlin
  Gynecologic Oncology.2012; 126(1): 41.     CrossRef
• Tumor angiogenesis: molecular pathways and therapeutic targets
  Sara M Weis, David A Cheresh
  Nature Medicine.2011; 17(11): 1359.     CrossRef
• Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma
  Jeong Won Jang, Seong Tae Park, Jung Hyun Kwon, Chan Ran You, Jong Young Choi, Chan-Kwon Jung, Si Hyun Bae, Seung Kew Yoon
  Experimental and Molecular Medicine.2011; 43(5): 305.     CrossRef
• Off-tumor target—beneficial site for antiangiogenic cancer therapy?
  Yihai Cao
  Nature Reviews Clinical Oncology.2010; 7(10): 604.     CrossRef
• Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
  Yihai Cao, Robert Langer
  Science Translational Medicine.2010;[Epub]     CrossRef
• New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future
  Melissa Taylor, Jochen Rössler, Birgit Geoerger, Gilles Vassal, Françoise Farace
  Expert Opinion on Investigational Drugs.2010; 19(7): 859.     CrossRef
• Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
  Hop S. Tran Cao, Michael Bouvet, Sharmeela Kaushal, Alex Keleman, Eric Romney, Ginna Kim, John Fruehauf, David K. Imagawa, Robert M. Hoffman, Matthew H.G. Katz
  Molecular Cancer Therapeutics.2010; 9(7): 2068.     CrossRef
• Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro
  Ahmed M. Al-Abd, Soo Hyeon Lee, Sun Hwa Kim, Jung-Ho Cha, Tae Gwan Park, Seung Jin Lee, Hyo-Jeong Kuh
  Journal of Controlled Release.2009; 137(2): 130.     CrossRef

Tumor angiogenesis has been related to the initiation as well as progression toward more aggressive behavior of human tumors. In particular, the activity of angiogenic factors is crucial for tumor progression. We previously characterized a secreted fibroblast growth factor-binding protein (FGF-BP) as a chaperone molecule, which binds to various FGFs, enhances FGF-mediated biochemical and biologic events and importantly is a crucial rate-limiting factor for tumor-dependent angiogenesis. We generated monoclonal antibodies that target FGF-BP protein and used them as a tool to evaluate frequency and pattern of FGF-BP expression during the malignant progression of pancreas and colorectal carcinoma in archival tissue samples. We found that FGF-BP is dramatically upregulated during the initiation of colorectal and pancreatic adenocarcinoma. Crucial genetic events underlying the initiation and progression of colorectal and pancreatic adenocarcinoma with a particular focus on the modulation of angiogenesis and antiangiogenic therapies are discussed. We propose that the upregulation of the secreted FGF-BP protein during early phases of pancreas and colon cancer could make this protein a possible serum marker indicating the presence of high-risk premalignant lesions. Furthermore, the biological activity of FGF-BP is neutralized by monoclonal antibodies suggesting the potential for antibody-based therapeutic targeting.

Citations

Citations to this article as recorded by  

• Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
  Shiqin Liu, Fernando Garcia-Marques, Chiyuan Amy Zhang, Jordan John Lee, Rosalie Nolley, Michelle Shen, En-Chi Hsu, Merve Aslan, Kashyap Koul, Sharon J. Pitteri, James D. Brooks, Tanya Stoyanova
  Scientific Reports.2021;[Epub]     CrossRef
• The roles and regulation of the KLF5 transcription factor in cancers
  Yao Luo, Ceshi Chen
  Cancer Science.2021; 112(6): 2097.     CrossRef
• Chaetocin: A review of its anticancer potentials and mechanisms
  Hangyu Jiang, Yuqi Li, Xiaocong Xiang, Zhili Tang, Kang Liu, Qiang Su, Xiaofen Zhang, Lin Li
  European Journal of Pharmacology.2021; 910: 174459.     CrossRef
• The potential role of tubeimosides in cancer prevention and treatment
  Md Sodrul Islam, Chenying Wang, Jingyou Zheng, Narayan Paudyal, Yongliang Zhu, Hongxiang Sun
  European Journal of Medicinal Chemistry.2019; 162: 109.     CrossRef
• Immune Cell Types and Secreted Factors Contributing to Inflammation-to-Cancer Transition and Immune Therapy Response
  Xingwei Chen, Chi Xu, Shengjun Hong, Xian Xia, Yaqiang Cao, Joseph McDermott, Yonglin Mu, Jing-Dong J. Han
  Cell Reports.2019; 26(7): 1965.     CrossRef
• Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response
  Qingyu Xu, Junfei Gu, You Lv, Jiarui Yuan, Nan Yang, Juan Chen, Chunfei Wang, Xuefeng Hou, Xiaobin Jia, Liang Feng, Guowen Yin
  Oncology Letters.2018;[Epub]     CrossRef
• The role of the signaling pathway FGF/FGFR in pancreatic cancer
  D. A. Gnatenko, E. P. Kopantsev, E. D. Sverdlov
  Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.2017; 11(2): 101.     CrossRef
• Role of fibroblast growth factors in pancreatic cancer
  D.A. Gnatenko, E.P. Kopantsev, E.D. Sverdlov
  Biomeditsinskaya Khimiya.2016; 62(6): 622.     CrossRef
• The anticancer effect of Huaier (Review)
  XIAOJIN SONG, YAMING LI, HANWEN ZHANG, QIFENG YANG
  Oncology Reports.2015; 34(1): 12.     CrossRef
• The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer
  Riccardo Giampieri, Mario Scartozzi, Michela Del Prete, Agnese Fulli, Luca Faloppi, Maristella Bianconi, Elena Maccaroni, Stefano Cascinu
  Cancer Treatment Reviews.2014; 40(8): 934.     CrossRef
• Desmoplasia in Pancreatic Cancer. Can We Fight It?
  E. E. Merika, K. N. Syrigos, M. W. Saif
  Gastroenterology Research and Practice.2012; 2012: 1.     CrossRef
• Anti-angiogenic and antitumor activities of Huaier aqueous extract
  XIAOLONG WANG, NING ZHANG, QIANG HUO, QIFENG YANG
  Oncology Reports.2012; 28(4): 1167.     CrossRef
• Identification of the Oxidative and Conjugative Enzymes Involved in the Biotransformation of Brivanib
  Jiachang Gong, Jinping Gan, Ramaswamy A. Iyer
  Drug Metabolism and Disposition.2012; 40(1): 219.     CrossRef
• Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology
  Jiachang Gong, Jinping Gan, Eric Masson, Shariq Syed, Yuan-Qing Xia, Daphne Williams, Janice Pursley, Mohammed Jemal, W. Griff Humphreys, Ramaswamy A. Iyer
  Drug Metabolism and Disposition.2012; 40(12): 2374.     CrossRef
• Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans
  Jiachang Gong, Jinping Gan, Janet Caceres-Cortes, Lisa J. Christopher, Vinod Arora, Eric Masson, Daphne Williams, Janice Pursley, Alban Allentoff, Michael Lago, Scott B. Tran, Ramaswamy A. Iyer
  Drug Metabolism and Disposition.2011; 39(5): 891.     CrossRef
• Effects of a Chinese Herbal Health Formula, “Gan-Lu-Yin”, on Angiogenesis
  Chun-Hsu Pan, I-Chun Hsieh, Fon-Chang Liu, Wen-Tsong Hsieh, Ming-Jyh Sheu, Ayano Koizumi, Chieh-Hsi Wu
  Journal of Agricultural and Food Chemistry.2010; 58(13): 7685.     CrossRef
• Tumor Angiogenesis Promoted by Ex vivo Differentiated Endothelial Progenitor Cells Is Effectively Inhibited by an Angiogenesis Inhibitor, TK1-2
  Ho-Kyun Oh, Jung-Min Ha, Eunju O, Byung Hun Lee, Suk Keun Lee, Byoung-Shik Shim, Yong-Kil Hong, Young Ae Joe
  Cancer Research.2007; 67(10): 4851.     CrossRef